* Adaptive Biotechnologies Corp ADPT.OQ ADPT.O is
expected
to show a rise in quarterly revenue when it reports results on
November 3.
* The Seattle Washington-based company is expected to
report a
21.7% increase in revenue to $48.03 million from $39.47 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Adaptive
Biotechnologies
Corp is for a loss of 38 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Adaptive
Biotechnologies Corp is $12, above its last closing price
of $8.41.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.41 -0.43 -0.37 Beat 14
Mar. 31 2022 -0.45 -0.46 -0.44 Beat 4.1
Dec. 31 2021 -0.47 -0.45 -0.43 Beat 4.7
Sep. 30 2021 -0.42 -0.42 -0.40 Beat 5
Jun. -0.42 -0.43 -0.35 Beat 18.1
30 2021
Mar. 31 2021 -0.41 -0.41 -0.29 Beat 29
Dec. 31 2020 -0.29 -0.29 -0.33 Missed -12.7
Sep. 30 2020 -0.29 -0.28 -0.27 Beat 5
This summary was machine generated November 2 at 00:52 GMT. All
figures in US dollars unless otherwise stated